Literature DB >> 11937868

Properties of osteoconductive biomaterials: calcium phosphates.

Racquel Zapanta LeGeros1.   

Abstract

Bone is formed by a series of complex events involving the mineralization of extracellular matrix proteins rigidly orchestrated by cells with specific functions of maintaining the integrity of the bone. Bone, similar to other calcified tissues, is an intimate composite of the organic (collagen and noncollagenous proteins) and inorganic or mineral phases. The bone mineral idealized as calcium hydroxyapatite, Ca10 (PO4)(6)(OH)2, is a carbonatehydroxyapatite, approximated by the formula: (Ca,X)(10)(PO4,HPO4,CO3)(6)(OH,Y)2, where X are cations (magnesium, sodium, strontium ions) that can substitute for the calcium ions, and Y are anions (chloride or fluoride ions) that can substitute for the hydroxyl group. The current author presents a brief review of CaP biomaterials that now are used as grafts for bone repair, augmentation, or substitution. Commercially-available CaP biomaterials differ in origin (natural or synthetic), composition (hydroxyapatite, beta-tricalcium phosphate, and biphasic CaP), or physical forms (particulates, blocks, cements, coatings on metal implants, composites with polymers), and in physicochemical properties. CaP biomaterials have outstanding properties: similarity in composition to bone mineral; bioactivity (ability to form bone apatitelike material or carbonate hydroxyapatite on their surfaces), ability to promote cellular function and expression leading to formation of a uniquely strong bone-CaP biomaterial interface; and osteoconductivity (ability to provide the appropriate scaffold or template for bone formation). In addition, CaP biomaterials with appropriate three-dimensional geometry are able to bind and concentrate endogenous bone morphogenetic proteins in circulation, and may become osteoinductive (capable of osteogenesis), and can be effective carriers of bone cell seeds. Therefore, CaP biomaterials potentially are useful in tissue engineering for regeneration of hard tissues.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937868     DOI: 10.1097/00003086-200202000-00009

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  249 in total

Review 1.  Stem cell and precursor cell therapy.

Authors:  Jingli Cai; Mahendra S Rao
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

2.  In vitro mineralization by preosteoblasts in poly(DL-lactide-co-glycolide) inverse opal scaffolds reinforced with hydroxyapatite nanoparticles.

Authors:  Sung-Wook Choi; Yu Zhang; Stavros Thomopoulos; Younan Xia
Journal:  Langmuir       Date:  2010-07-20       Impact factor: 3.882

Review 3.  Aging and bone.

Authors:  A L Boskey; R Coleman
Journal:  J Dent Res       Date:  2010-10-05       Impact factor: 6.116

4.  Review of bone substitutes.

Authors:  Landon S Pryor; Earl Gage; Claude-Jean Langevin; Fernando Herrera; Andrew D Breithaupt; Chad R Gordon; Ahmed M Afifi; James E Zins; Hal Meltzer; Amanda Gosman; Steve R Cohen; Ralph Holmes
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2009-10

Review 5.  Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: a review.

Authors:  Susmita Bose; Solaiman Tarafder
Journal:  Acta Biomater       Date:  2011-11-20       Impact factor: 8.947

6.  Comparison study of biomimetic strontium-doped calcium phosphate coatings by electrochemical deposition and air plasma spray: morphology, composition and bioactive performance.

Authors:  Ling Li; Xia Lu; Yizhi Meng; Christopher M Weyant
Journal:  J Mater Sci Mater Med       Date:  2012-04-18       Impact factor: 3.896

7.  Bioceramic-mediated trophic factor secretion by mesenchymal stem cells enhances in vitro endothelial cell persistence and in vivo angiogenesis.

Authors:  Jiawei He; Martin L Decaris; J Kent Leach
Journal:  Tissue Eng Part A       Date:  2012-06-07       Impact factor: 3.845

8.  Runx2 overexpression in bone marrow stromal cells accelerates bone formation in critical-sized femoral defects.

Authors:  Abigail M Wojtowicz; Kellie L Templeman; Dietmar W Hutmacher; Robert E Guldberg; Andrés J García
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

9.  The use of beta-TCP in the surgical treatment of tibial plateau fractures.

Authors:  Chao Shen; Jie Ma; Xiao-Dong Chen; Li-Yang Dai
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2009-02-24       Impact factor: 4.342

10.  Nanostructured calcium phosphate coatings on magnesium alloys: characterization and cytocompatibility with mesenchymal stem cells.

Authors:  Maria Emil Iskandar; Arash Aslani; Qiaomu Tian; Huinan Liu
Journal:  J Mater Sci Mater Med       Date:  2015-04-28       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.